AIDS: A new treatment could be a "revolution in immunization"

You are in Home => First Quarter 2016 => AIDS: A new treatment could be a "revolution in immunization"
First Quarter 2016

Dr Erwann Loret explains how his experimental treatment offers hope for AIDS patients.

the man of the day

AIDS: an "incentive" treatment in the fight against the AIDS virus

There will be a cure for AIDS someday.? A therapeutic vaccine from Marseille gives hope. Three years after launching the clinical trials around this treatment, three of the nine patients treated by this vaccine and infected with HIV have seen their infected cells become undetectable in the blood. Dr Erwann Loret, at the origin of this experimentation, confirms that these results are "encouraging" but caution is needed not to jump to conclusions. "In my intuition I feel we will be able to talk about the hope of healing when these patients do the retro-seroconversion, when the immune system will no longer detect infected cells and will reduce the antibody rate. This moment is not right up there, explains the scientist carefully, on Tuesday, March 15.

This treatment also seems to be "quite rightly a revolution in vaccination". Unlike the usual vaccines, it "uses a synthetic protein and there is no use of adjuvants". In other words, it is not a matter of inoculating in the body harmless parts of the virus to accelerate the disappearance of diseased cells. "It's a different approach to vaccination against AIDS," confirms Dr. Erwann Loret.

One million euros

Within this test, 46 patients under tritherapy has followed the protocol for the period of twelve months. To ensure their effectiveness, the doctors also proceeded to interruptions in the treatment of two months. It was then time to verify that the virus did not reappear in the form of a "rebound viremic"Which would not occur among volunteers receiving placebo.
These clinical trials will take place at the Clinical Research Center of the project hospital in Marseille, doctors were able to rely on the financial support of the French Biosantech start-up and crowdfunding on the Internet. "Clinical trials are very expensive. The arrival of Biosantech was a real blessing since these tests have a cost of more than one million euros, "Recalls Dr Erwann Loret, who hopes, now that other hospitals begin to apply this method and take advantage of this treatment and" verify the outcome. "

Translated from French with poor support technology of the original written by Babylon MARC-OLIVIER Fogiel , JULIEN ABSALON published in 15 / 03 / 2016 at 23: 21 by Claudio Souza and Revised by Mara MacedoIn 18 / 03 / 2016

Comment and Socialize. Life is better with friends!

This site uses Akismet to reduce spam. Learn how your feedback data is processed.

This Site uses Cookies and you may refuse this use. But you may well know what is being recorded in consonance with our política the privatization cidade